Operating loss for third quarter of 2012 was $5.53m compared to operating loss of $10.35m for the third quarter of 2011.
The company reported a net loss of $16.09m, or $0.22 per share, for the nine months ended 30 September 2012 compared to a net loss of $19.75m, or $0.30 per share, for the nine months ended 30 September 2011.
Operating loss of $20.40m was reported for the first nine months of 2012 compared to operating loss of $20.05m for the first nine months of 2011.
Keryx chief executive officer Ron Bentsur said the company is looking forward to reporting the top-line data from its long-term Phase 3 study of Zerenex and anticipating the NDA filing for the indication in the first quarter of 2013.
"We are also excited to have recently initiated our Phase 2 study exploring Zerenex in the non-dialysis dependent chronic kidney disease setting, which we believe represents a substantial potential additional opportunity for Zerenex," Bentsur added.